October 2020

ASBM Launches New Microsite on Forced Switching in Canada On October 28th, ASBM launched a new microsite focused on the issue of forced biosimilar substitution in Canada- the forcing of patients off their physician-prescribed biologics and onto preferred government-chosen products.   www.NoForcedSwitching.ca   This controversial practice is rare among the advanced countries of the world, […]

Read More


July-August 2020 Newsletter

GaBI Publishes ASBM Whitepaper on European Physician Survey On August 28th, the Journal of the Generics and Biosimilars Initiative (GaBI Journal) published a whitepaper entitled “European prescribers’ attitudes and beliefs on biologicals prescribing and automatic substitution”. The paper explores in detail the findings of ASBM’s survey of 579 prescribers of biologic medicines from 10 practice areas in 6 Western […]

Read More


June 2020 Newsletter

Comment Period on NIOSH Hazardous Drugs List Extended to July 30th    The National Institute for Occupational Safety and Health (NIOSH) has extended the comment period regarding its proposed Hazardous Drugs List additions for 2020. The comments on the proposed list are now due July 30th. Several biologic medicines have been proposed- in ASBM’s view inappropriately- […]

Read More


April-May 2020 Newsletter

  newsletter | April-May 2020 issue 88       Who We Are The Alliance for Safe Biologic Medicines is an organization composed of patients, physicians, pharmacists, biotechnology companies that develop innovative and biosimilar medicines, and others who are working together to ensure that patient safety is at the forefront of the biosimilars policy discussion. […]

Read More


March 2020 Newsletter

ASBM Whitepaper: Lessons from European Biosimilar Markets On March 25th, the Journal of the Generics and Biosimilars Initiative (GaBI Journal) published a whitepaper entitled Policy recommendations for a sustainable biosimilars market: lessons from Europe. The paper was authored by ASBM Executive Director Michael Reilly and Advisory Board Chair Philip Schneider.   The biosimilar market in Europe is the […]

Read More


February 2020 Newsletter

newsletter | February 2020 issue 85       Who We Are The Alliance for Safe Biologic Medicines is an organization composed of patients, physicians, pharmacists, biotechnology companies that develop innovative and biosimilar medicines, and others who are working together to ensure that patient safety is at the forefront of the biosimilars policy discussion. It […]

Read More


January 2020 Newsletter

newsletter | January 2020 issue 84       Who We Are The Alliance for Safe Biologic Medicines is an organization composed of patients, physicians, pharmacists, biotechnology companies that develop innovative and biosimilar medicines, and others who are working together to ensure that patient safety is at the forefront of the biosimilars policy discussion. It […]

Read More


December 2019 Newsletter

Canadian Biosimilar Stakeholder Consultation Survey Open Until January 13   The Canadian Agency for Drugs and Technologies and Health (CADTH), in conjunction with the pan-Canadian Pharmaceutical Alliance (pCPA) – is leading a consultation on the use and implementation of biosimilars. ASBM encourages Canadian stakeholders- particularly those in the patient and physician communities who are  concerned with […]

Read More


November 2019 Newsletter

newsletter | November 2019 issue 82       Who We Are The Alliance for Safe Biologic Medicines is an organization composed of patients, physicians, pharmacists, biotechnology companies that develop innovative and biosimilar medicines, and others who are working together to ensure that patient safety is at the forefront of the biosimilars policy discussion. It […]

Read More


October 2019 Newsletter

newsletter | October 2019 issue 81 Who We Are The Alliance for Safe Biologic Medicines is an organization composed of patients, physicians, pharmacists, biotechnology companies that develop innovative and biosimilar medicines, and others who are working together to ensure that patient safety is at the forefront of the biosimilars policy discussion. It is the mission […]

Read More